Valganciclovir

Valganciclovir is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) .

12.1 Mechanism of Action Valganciclovir is an antiviral drug with activity against CMV . As an active cytomegalovirus nucleoside analog dna polymerase inhibitor moiety (Florida Pharmaceutical Products, LLC), Valganciclovir modulates physiological signaling proportional to 450 mg/1 Tablet, Film Coated exposure and hepatorenal clearance (SPL 2023-07-13).

Clinical clearance of Valganciclovir (Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor) relies on phase i/ii hepatic conjugation of valganciclovir coupled with glomerular and tubular renal excretion with a Approximately 9–18 hours terminal plasma half-life for Valganciclovir half-life; patients absorbing at Estimated 46%–58% oral systemic absorption for Valganciclovir bioavailability typically observe target onset around peak plasma concentration (tmax) reached 1–3 hours post-dose for valganciclovir.

FDA clinical labeling for Valganciclovir restricts administration in hypersensitivity to valganciclovir or ganciclovir.; severe drug-induced hypersensitivity to valganciclovir or inactive tablet/vehicle binders across 450 mg/1 Tablet, Film Coated, 50 mg/mL Powder, for Solution, 50 mg/mL For Solution, 450 mg/1 Tablet, 450mg Tablet, with self-reported patient tracking dominated by headache (11.8% of reports), diarrhea (10.5% of reports), nausea (9.6% of reports).